GemVax and Samsung Pharm has launched its pancreatic cancer vaccine in Korea for the first time in the world
The GemVax’s pancreatic cancer vaccine, Liavax(code name: GV1001), has been acquired the final sale approval from the Ministry of Food and Drug Safety.
Liavax, a pharmaceutical product approved for the 21st time as a pancreatic cancer treatment from the Ministry of Food and Drug Safety on the l...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
